REVIMMUNE
Live / Registered — Registered (as of 15 Feb 2022)
What this means for you
Registered since 15 Feb 2022. The owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 88983477
- Registration number
- 6647373
- Mark type
- Stylized text
- Filed
- 19 Nov 2018
- Published for opposition
- 09 Apr 2019
- Registered
- 15 Feb 2022
- Attorney of record
- Keith W. Medansky
Goods and services
- Class 042 — Scientific and technological services: Research and development of biologicals and pharmaceuticals in the prevention and treatment of blood disease and cancer, viral and other infectious diseases, and the modulation and treatment of immune system related diseases and disorders
Owner
- RevImmune, Inc., Bethesda, MD, US
- RevImmune, Inc., Bethesda, MD, US
- RevImmune, Inc., Bethesda, MD, US
Prosecution history
- 15 Feb 2022 — REGISTERED-PRINCIPAL REGISTER
- 12 Jan 2022 — NOTICE OF ACCEPTANCE OF STATEMENT OF USE E-MAILED
- 11 Jan 2022 — ALLOWED PRINCIPAL REGISTER - SOU ACCEPTED
- 08 Dec 2021 — STATEMENT OF USE PROCESSING COMPLETE
- 29 Nov 2021 — USE AMENDMENT FILED
- 08 Dec 2021 — DIVISIONAL PROCESSING COMPLETE
- 29 Nov 2021 — DIVISIONAL REQUEST RECEIVED
- 08 Dec 2021 — CASE ASSIGNED TO INTENT TO USE PARALEGAL
- 29 Nov 2021 — TEAS STATEMENT OF USE RECEIVED
- 29 Nov 2021 — TEAS REQUEST TO DIVIDE RECEIVED
- 27 May 2021 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 25 May 2021 — SOU EXTENSION 4 GRANTED
- 25 May 2021 — SOU EXTENSION 4 FILED
- 25 May 2021 — SOU TEAS EXTENSION RECEIVED
- 26 Nov 2020 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED